

PATIENT ALERT CARD



XELJANZ[®] 
[tofacitinib citrate]
5 mg tablets

This card contains important safety information that you need to be aware of before you start taking XELJANZ and during your treatment with XELJANZ. If you do not understand this information, please ask your doctor/pharmacist to explain it to you.

- Keep this card with you and show it to any doctor or pharmacist involved in your care.
- See the XELJANZ package leaflet for more information.
You should use XELJANZ following the package leaflet.

Tell your doctor or your pharmacist about ALL the medicines you are taking, including prescription and non-prescription medicines, vitamins and herbal supplements.

XELJANZ is not recommended for use with biologic DMARDs for rheumatoid arthritis or with certain other medicines that depress your immune system (e.g. azathioprine, tacrolimus, cyclosporine or mycophenolate). Taking XELJANZ with these medicines may increase your risk of infection.

During treatment with XELJANZ

Tell your doctor immediately if you:

- Develop symptoms of an infection, such as fever, persistent cough, weight loss, or excessive tiredness. XELJANZ may increase your risk of getting infections, which can become serious if not treated.
You may be at a higher risk for infections if you are 65 years of age or older, have diabetes, chronic lung disease, or are taking corticosteroids.
Your XELJANZ treatment may be stopped by your doctor.
- Develop any painful skin rash or blisters.
- Have been in close contact with a person with tuberculosis.
- Develop symptoms of shortness of breath.

- Develop abdominal signs and symptoms such as stomach pain, abdominal pain, blood in your stool, or any change in your bowel habits with fever.
- Notice any new growth on the skin or any changes in existing moles or spots.
- Develop yellow skin, nausea or vomiting.
- Are due to receive any vaccine. You should not receive certain types of vaccines while taking XELJANZ.
- Become pregnant or plan on becoming pregnant. XELJANZ should not be used during pregnancy.
Women of childbearing potential should be advised to use effective contraception during treatment with XELJANZ and for at least 4 weeks after the last dose.
- Women should not breastfeed while being treated with XELJANZ.

- If you develop symptoms suggestive of congestive heart failure or worsening of existing congestive heart failure, such as shortness of breath, swelling of ankles, persistent cough or fatigue, seek medical attention immediately.

Other information *[please complete]*

Patient's Name:

Doctor's Name:

Doctor's Phone:

Doctor's Fax:

If you stop taking XELJANZ, keep this card with you for at least 2 months after taking the last dose of XELJANZ

